Understanding the Impact of Tailored Radiotherapy in Breast Cancer Treatment
A recent study has shed light on the effectiveness of adjusting the extent of locoregional radiotherapy (RT) based on the response of lymph nodes to primary systemic treatment (PST) in breast cancer patients. The findings suggest that this approach is not only safe but also leads to low recurrence rates, offering a more personalized treatment strategy.
The research was presented at the annual European Breast Cancer Conference, which took place from March 25 to 27 in Barcelona, Spain. Fleur Mauritz, M.D., from the Maastricht University Medical Center in the Netherlands, led the study, which focused on the long-term safety and outcomes of tailoring RT based on the ypN-status—indicating the status of lymph nodes after PST.
Study Methodology and Patient Groups
The study involved 848 patients who underwent PST followed by either lumpectomy or mastectomy. These procedures were combined with sentinel lymph node biopsy and/or marked axillary lymph node removal or axillary lymph node dissection (ALND). Based on their ypN-status, participants were categorized into three risk groups:
- Low-risk group (ypN0): Patients with no evidence of cancer in the lymph nodes.
- Intermediate-risk group (ypN1): Patients with limited spread of cancer to the lymph nodes.
- High-risk group (ypN2+): Patients with extensive involvement of the lymph nodes.
Radiation therapy was then tailored according to each group’s risk level:
- Low-risk group: Whole breast RT (WBRT) after lumpectomy or no RT after mastectomy.
- Intermediate-risk group: WBRT or chest wall RT, along with radiation to axillary levels 1 to 2, especially if ALND was not performed.
- High-risk group: WBRT or chest wall RT, targeting the nonresected part of the axilla, with or without internal mammary nodes RT.
Long-Term Outcomes and Survival Rates
Of the 848 patients, 838 completed follow-up. The results showed promising long-term outcomes across all groups:
- 10-year locoregional recurrence rate (LRR): 2.9% overall, with 2.4%, 3.2%, and 2.8% for the low-, intermediate-, and high-risk groups, respectively.
- 10-year recurrence-free interval (RFI): 79.2% overall, with significant differences between groups: 88.2% for the low-risk group, 78.9% for the intermediate-risk group, and 64.9% for the high-risk group.
- 10-year overall survival (OS): 83.0% overall, with 90.7%, 83.0%, and 70.5% for the low-, intermediate-, and high-risk groups, respectively.
These findings highlight the importance of individualized treatment plans, as they demonstrate that even in higher-risk groups, the recurrence rates remain relatively low when RT is appropriately adjusted.
Implications for Breast Cancer Care
Mauritz emphasized the significance of this approach, stating that tailoring the extent of radiotherapy based on how well chemotherapy has worked to treat cancer in the lymph nodes leads to very low and reassuring recurrence rates in the breast and surrounding area.
This study provides valuable insights into the evolving landscape of breast cancer treatment. By using ypN-status to guide radiation therapy decisions, healthcare providers can offer more precise and effective care, potentially reducing unnecessary treatments while maintaining high survival rates.
As the medical community continues to explore personalized approaches to cancer care, this research underscores the potential benefits of adapting treatment strategies to individual patient responses. It also highlights the importance of ongoing follow-up and monitoring to ensure long-term success and patient well-being.
